AKT1 E17K mutant phosphorylates BAD

Stable Identifier
R-HSA-2399941
Type
Reaction [transition]
Species
Homo sapiens
Compartment
cytosol
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
AKT1 E17K mutant phosphorylates BAD
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
AKT1 E17K gain-of-function mutant phosphorylates BAD (Guo et al. 2010). AKT-mediated BAD phosphorylation inactivates BAD, thereby preventing BAD-mediated apoptosis (Del Peso et al. 1997).
Literature References
PubMed ID Title Journal Year
20440266 Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells

Wang, S, Guo, G, Wang, Z, Wang, G, Chen, JL, Chen, Y, Chen, Y, Rothman, PB, Qiu, X

Oncogene 2010
9381178 Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

Page, CP, Nunez, G, Gonzalez-Garcia, M, Herrera, R, del Peso, L

Science 1997
Participants
Input
Output
Participates
as an event of
Catalyst Activity

protein serine/threonine kinase activity of p-T308,S473-AKT1 E17K [cytosol]

Physical Entity
p-T308,S473-AKT1 E17K [cytosol] (Homo sapiens)
Activity
protein serine/threonine kinase activity (GO:0004674)
Normal reaction
AKT phosphorylates BAD (Homo sapiens)
Functional status

Gain of function of p-T308,S473-AKT1 E17K [cytosol]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2012-07-18)
Reviewed
Zhao, JJ  (2012-08-13)
Yuzugullu, H  (2012-08-13)
Thorpe, L  (2012-08-13)
Created
Orlic-Milacic, M  (2012-07-13)
Cite Us!